Lisa Shafer

Company: Biogen

Job title: Vice President - Product Development & Reg Chemistry, Manufacturing, Controls, Medical Devices & Packaging

Bio:

𝗟𝗶𝘀𝗮 𝗦𝗵𝗮𝗳𝗲𝗿 𝗶𝘀 𝗮𝗻 𝗮𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗲𝗱 𝗮𝗻𝗱 𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗹𝗲 𝗲𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 renowned for her visionary leadership, seamlessly integrating scientific expertise, technological innovation, and strategic acumen to drive development of cutting-edge therapies. She is known for leveraging insight, foresight, and a holistic industry perspective to propel development of therapies that converge med-tech and biopharma.

Lisa has championed groundbreaking initiatives to elevate overall healthcare value in Fortune 200 corporations and nimble start-ups in the biopharmaceutical, medical device, and medical technology domains within both public and private sectors. Lisa currently leads Product Delivery Solutions for Biogen, focusing on end-to-end delivery of patient centric drug- device combination products and packaging technologies.

An experienced board member and advisor, Lisa currently serves as an Advisory Board Member for Alcyone Therapeutics, and Neuraworx Medical Technologies, Inc.

Seminars:

Panel Discussion: Matching Mechanism to Disease – Optimizing CNS Delivery Strategies Across Indications to Enhance Treatment Efficacy & Safety 4:30 pm

Where systemic vs. direct (e.g., IT, ICV, convection-enhanced) routes are used How targeting location, BBB access, and regional specificity guide decision-making The impact of disease stage and progression on delivery strategyRead more

day: Day One - Afternoon

Round-table Discussion: Straight to the Targett: Exploring the Role of Direct CNS Access in Modern Therapeutics to Solidify Local Administration in the Clinic 2:00 pm

Highly interactive breakout discussions designed to crowdsource solutions, share cross-functional insights, and explore the practical barriers to clinical adoption. What safety, procedural, or monitoring strategies are most critical to de-risk intra- CSF and other direct CNS delivery methods in clinical trials? How can integration between therapeutic formulation and delivery systems be optimized to accelerate approval…Read more

day: Day One - Afternoon - Track B

Chair’s Opening Remarks 8:45 am

Read more

day: Day One - Morning